It has been over 50 years since a review has focused exclusively on the monoamine oxidase (MAO) inhibitor tranylcypromine (TCP). A new review has therefore been conducted for TCP in two parts which are written to be read preferably in close conjunction: part I -pharmacodynamics, pharmacokinetics, drug interactions, toxicology; and part II -clinical studies with meta-analysis of controlled studies in depression, practice of TCP treatment, place in therapy. The irreversible and nonselective MAO-A/B inhibitor TCP has been confirmed as an efficacious and safe antidepressant drug. For the first time, a meta-analysis of controlled clinical trials in depression demonstrated that TCP is superior to placebo (pooled logOR = 0.509, 95%CI = 0.026 to 0.993, 4 studies) and equal to other antidepressants (pooled logOR = 0.208, 95%CI = À 0.128 to 0.544, 10 studies). In treatment resistant depression (TRD) after tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs), TCP was superior to placebo (logOR = 2.826, 95%CI = 1.494 to 4.158, one study) and non-established antidepressants (pooled logOR = 1.976, 95%CI = 0.907 to 3.045, 4 studies), and was equal to other MAO inhibitors and an antidepressant combination (pooled logOR = À 0.366, 95%CI = À 0.869 to 0.137, 4 studies). Controlled studies revealed that TCP might provide a special advantage in the treatment of atypical depression, which was supported by a recent PET study of MAO-A activity in brain. However, TCP treatment remains beset with the need for a mandatory tyraminerestricted diet and is therefore limited to use as a third-line antidepressant according to recent treatment algorithms and guidelines for depression treatment. On the other hand, the effort needed to maintain a tyramine-restricted diet may have been overestimated in the perception 
of both doctors and patients, which may have led to relative underuse of TCP. Interaction with serotonergic drugs bears the risk of severe serotonin toxicity (SST) and combination with indirect sympathomimetic drugs may result in hypertensive crisis which both adds to the risks of TCP. At the same time, TCP has low to no risks of central anticholinergic, sedative, cardiac conduction, body weight, hemostatic effects, or pharmacokinetic drug interactions. Neuroprotection by MAO inhibitors due to reduced oxidative stress is becoming increasingly studied. Taken together, TCP is being increasingly recognized as an important option in systematic treatment approaches for patients suffering from severe courses of depression, such as TRD and atypical depression, by offering a MAO-related pathophysiological rationale. & 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
A general introduction to this review part II on tranylcypromine (TCP) has already been given in part I (pharmacology) of the joined reviews. Consecutively, the main data of the clinical pharmacology of TCP are presented here which includes, for the first time, a meta-analysis of controlled studies in depression. A discussion of the clinical practice of TCP treatment is added referring to special requirements of this irreversible monoamine oxidase (MAO)-A/B inhibitor. This is completed by an overview of the state of the art discussion in medical literature concerning the benefit-risk ratio and place in therapy of TCP.
Experimental procedures
The experimental procedures of the review have already been presented in part I.
For the meta-analysis, controlled studies of TCP monotherapy in depression have been identified from tabular compilations in two comprehensive reviews covering the periods before 1965 (Atkinson and Ditman, 1965) and before 1993 (Thase et al., 1995) . Considering these studies in the previous reviews was regarded as a sufficient quality standard; however, no violations in minimal quality requirements for the target of this meta-analysis were detected in our own evaluation (prospective parallel or cross-over, open, single-blind or double-blind study, placebo or active drug comparator, only depressive patients, acute treatment, no antidepressant comedication, sufficient description, and minimum of 10 patients). Studies after 1993 were searched in MedLine using the search terms tranylcypromine and depression. Data of published study reports have been extracted and documented by one author (SU) and the file has been confirmed by another author (RR). Six studies were found that compared TCP with placebo (Bartholomew, 1962; Glick, 1964; Gottfries, 1963; Khanna et al., 1963; Himmelhoch et al., 1982; White et al., 1984) and 19 studies with active comparator: the TCAs imipramine (Freyhan, 1960; Himmelhoch et al., 1991; Spear et al., 1964; Thase et al., 1992a) , amitriptyline (O'Brien et al., 1993; Razani et al., 1983; White et al., 1980a) , imipramine and amitriptyline (Richmond and Roberts, 1964) , and nortriptyline (White et al., 1984) , the MAO inhibitors phenelzine (Birkenhäger et al., 2004; Glick, 1964) , brofaromine (Nolen et al., 1993; Volz et al., 1994a Volz et al., , 1994b , and moclobemide (Heinze et al., 1993) , the serotonin precursor L-5-hydroxytryptophan (Nolen et al., 1985) , the dopamine and norepinephrine reuptake inhibitor nomifensine (Nolen et al., 1988) , the combination of venlafaxine and mirtazapine (McGrath et al., 2006) , and lamotrigine (Nolen et al., 2007) . Eight studies were conducted between 1960 and 1964 (early studies). The remaining 17 studies all were conducted between 1980 and 2007 (late studies). Of the 25 studies, 17 were double-blind randomized trials, 5 early studies (62.5% of early studies) and 12 late studies (70.6% of late studies). One study was single-blind, 5 studies were open label, and 22 were randomized. Modern criteria of psychiatric diagnosis, such as Diagnostic and Statistical Manual of Mental Disorders (DSM III or IV) were used in the studies after 1980. Only 4 studies did not use a structured and validated rating scale, such as the Hamilton Depression Scale (HAMD). As these were early studies, this marks the only important difference between early and late studies. It is therefore concluded that the quality of studies was high for the 1536 patients included, with 664 patients receiving TCP (Tables 1, 2 ).
The effect size of studies was calculated as the log odds ratio (logOR) of the number of treatment responders and nonresponders in TCP and control group, which were categorized according to 50% HAMD improvement as a cut-off point in the majority of studies or according to a predefined level of Clinical Global Impression (CGI) improvement or similar in the remaining studies. A standard continuity correction of 0.5 was applied to one study that included nil cells. All patients randomized or later defined as drop-outs were included in the analysis (intention-to-treat sample; ITT). Drop-outs were set as nonresponders for studies lacking these detailed data. In three studies without ITT data, transformation of completer's data to ITT data according to the mean ratio of completer's and ITT data of the other studies was needed. The summary effect size was calculated as the pooled logOR according to a fixed effect model in a Microsoft Excel spreadsheet (D'Agostino and Weintraub, 1995; Neyeloff et al., 2012) .
In the case of heterogeneity of studies, explorative sensitivity analyses were conducted with respect to subgroups of studies using treatment resistant depression (TRD) versus non-TRD in a first approach and pharmacological group of comparator drug as a second approach for group parameters to obtain homogeneous data sets. This resulted in four pooled odds ratios according to homogeneous data sets for TCP versus placebo in non-TRD, TCP versus comparator antidepressant in non-TRD, and two times for TCP versus comparator antidepressant in TRD according to two different drug groups.
3. Clinical studies and therapeutic experience with tranylcypromine 3.1. Meta-analysis of prospective controlled studies in depression Meta-analyses of TCP in depression including formal statistical calculations of overall effect size (e.g., with pooled odds ratios), are currently lacking in the literature. Therefore, we conducted a meta-analysis to compare TCP with other antidepressants and placebo. Experimental procedures are described in paragraph 2. The results of individual studies are summarized in Table 3 .
3.1.1. Comparison with placebo in depression Accordingly, the comparison with placebo in 5 studies (no data available in one other study) revealed a pooled logOR = 0.779 with 95% confidence interval (CI) = 0.324 to 1.233 not crossing zero. However, the set of data was inhomogeneous with Χ 2 = 10.9, df = 4, and p o 0.05 because of one outlier placebo controlled study in TRD showing a very high effect size of logOR = 2.826 and 95% CI = 1.494 to 4.158 (Himmelhoch et al., 1982) . Excluding this study, however, still provided a pooled logOR = 0.509 with 95%CI = 0.026 to 0.993 not crossing zero and formal confirmation of homogeneity (Χ 2 = 0.64, df = 3, p 4 0.05). This is at the upper end of the effect size of antidepressants compared to placebo of 0.39 (95%CI 0.24 to 0.54) (Bauer et al., 2013) . The one study without available data for the meta-analysis also estimated TCP being more efficacious than placebo (Khanna et al., 1963) . TCP is therefore superior to placebo in the treatment of depression at a p = 0.05 significance level (Figure 1 ).
Comparison with antidepressants in depression other than treatment resistant depression (TRD).
The comparison with antidepressant drugs in 18 studies (no data available in one other study) resulted in a pooled logOR = 0.156 with 95%CI = -0.114 to 0.426 crossing zero and formal inhomogeneity of the data set (Χ 2 = 29.72, df = 17, po0.05). Excluding eight of these studies which were done in TRD, the picture remained similar, however, whereby formal homogeneity was confirmed (pooled logOR = 0.208 with 95% CI = -0.128 to 0.544; homogeneity: Χ 2 = 10.31, df = 9, p40.05). The one study without available data for the metaanalysis also estimated TCP being as efficacious as imipramine (Spear et al., 1964) . Therefore, we conclude, based on the comparator drugs investigated in this sample, that TCP is as efficacious as TCAs and other MAO inhibitors in non-TRD (Figure 2 ).
Comparison with antidepressants in treatment resistant depression (TRD)
The comparator drugs were more variable in studies of TRD. A plausible subgrouping was therefore conducted according to the therapeutic status as established or non-established antidepressant (or antidepressant combination, or sequence of antidepressants). Nevertheless, this remains a rather artificial and subjective approach. Thus, an antidepressant drug combination (McGrath et al., 2006) and MAO inhibitors (Birkenhäger et al., 2004; Nolen et al., 1993; Volz et al., 1994a ) (active comparator in TRD: group 1) as well as L-5-hydroxytryptophan (Nolen et al., 1985) , nomifensine (Nolen et al., 1988) , lamotrigine (Nolen et al., 2007) , and a small study of a TCA after non-response to TCP in cross-over design (Thase et al., 1992a ) (active comparator in TRD: group 2) formed the two subgroups. Formal inhomogeneity resulted in a combined analysis, and homogeneous data sets resulted in Bartholomew, 1962 Reactive, endogenous, involutional 25-67 m/f out Gottfries, 1963 Endogenous, neurotic, other n.d. n.d. in Khanna et al., 1963 n.d. 24-47 f in Spear et al., 1964 Endogenous, atypical 44.5 m/f in/out Richmond and Roberts, 1964 Endogenous, atypical n.d. n.d. out Glick, 1964 Involutional separate meta-analyses of the two drug groups. TCP was equal to comparators in the meta-analysis with MAO inhibitors and drug combination (group 1: pooled logOR = -0.366 with 95%CI = -0.869 to 0.137; homogeneity: Χ 2 = 1.54, df = 3, p 4 0.05), and it was clearly superior to the nonor less established antidepressants, including TCA after TCP (group 2: pooled logOR = 1.976 with 95%CI = 0.907 to 3.045; homogeneity: Χ 2 = 2.51, df = 3, p 4 0.05) (Figure 3 ). A comparison of these results with a meta-analysis published in 1995, which included studies conducted until 1992, is difficult because the database had 10 fewer studies and subgrouping of studies according to in-and outpatients only. TCP response was higher than placebo and active comparators in all tests; however, there was no confirmation of statistical significance (Thase et al., 1995) . As a general conclusion of the present meta-analysis with calculation of pooled odds ratios, TCP exhibited clear antidepressant activity in the clinical assessment, which was superior to placebo and similar to the active comparator. Unfortunately, no controlled studies have been conducted to compare TCP with antidepressants introduced after 1985, such as SSRIs, SSNRIs, mirtazapine, trazodone, bupropion, or agomelatine. Figure 1 Effect sizes and summary effect sizes calculated as log odds ratios and pooled log odds ratios as well as their 95% confidence intervals for clinical studies of tranylcypromine and placebo in depression (*non-homogenous, study (5) in treatment resistant depression, the numbers above confidence intervals indicate the numbers of responders and non-responders after tranylcypromine (first pair) and placebo (second pair)).
Non-interventional clinical studies to compare the efficacy of tranylcypromine with SSRIs and moclobemide in depression
In a practice-based observational study conducted in Canada, 213 DSM-III depressed outpatients were investigated in 2677 visits by means of the Montgomery-Asberg Depression Rating Scale (MADRS) and survival statistics over two years. Time to MADRS below a cut-off of 18 was significantly lower for treatment with MAO inhibitors (61% TCP) or TCAs compared to SSRIs and a heterogeneous group of "atypical" antidepressants (71% bupropion), and the overall time spent below the cut-off was longer for MAO inhibitors and TCAs (Mittmann et al., 1999 ). An Australian study over 12 months in DSM-IV depressive patients of the more severe and treatment resistant type also compared irreversible MAO inhibitors (n = 18 treatments), TCAs (n = 67), SSRIs (n = 71), and moclobemide (n = 22). Irreversible MAO inhibitors among drug groups received the highest rating as a helpful intervention (56%), had the highest ratio of full remission among the ratings as helpful intervention (53%), and received the lowest ratings that spontaneous remission may have been added (17%) or concomitant treatment was more likely to be responsible (11%) to the treatment effect. For example, the corresponding ratios were 48%, 29%, 56%, and 23% for SSRIs. The data were evaluated by the authors as suggestive of an advantage in efficacy for irreversible MAO inhibitors and TCAs over SSRIs and moclobemide (Parker et al., 2001) . A retrospective analysis of the data from a trial in bipolar depression revealed a recovery rate of 53% for 30 patients on TCP, but only 27% for 22 patients on paroxetine, with a significant difference in the survival statistics (p = 0.029) (Mallinger et al., 2009) . Switch studies of TCP to moclobemide, which seemed to be a reasonable approach after the development of the reversible MAO inhibitor, resulted in a disappointing outcome in two studies. For example, in 30 stable patients receiving 10-20 mg/day TCP, 28 suffered from a relapse after the switch to 450-600 mg/day moclobemide (Gosciniak, 1997; Vink et al., 1994) . Our literature search in MedLine using the search term tranylcypromine revealed no other studies comparing TCP with SSRIs or other antidepressants typically used in most patients today.
Tranylcypromine in subtypes of depression
A good chance for a differential treatment of depression is theoretically expected for TCP because it displays a special mechanism of action and is at the extreme for psychomotor activating and non-sedating properties of antidepressants. Recent studies of MAO in the pathophysiology of depression as presented in paragraph 3.1 of review part I support this rationale. However, the intersection of diagnostic criteria, changes in terminology, a limited number of studies, and variability in study design complicated the definition of subtypes of depression, which may be preferentially treated by TCP.
Atypical depression
Atypical depression in terms of reversed neurovegetative symptoms (anergia, motor retardation, hyperphagia, and hypersomnia), mood reactivity, and interpersonal rejection sensitivity, which was previously considered as reactive or non-endogenous depression (including diagnostic differences), was even linked to a good MAO inhibitor response in the definitions by some authors (Pae et al., 2009; Parker et al., 2002) . A recent study thus confirmed increased MAO-A activity for this subtype of depressive disorders (Chiuccariello et al., 2014) . Increased platelet MAO-B activity has already been reported in previous studies (White et al., 1980b) and differentiation of atypical depression as a genetically-specific subtype related to MAO Figure 3 Effect sizes and summary effect sizes calculated as log odds ratios and pooled log odds ratios as well as their 95% confidence intervals for clinical studies of tranylcypromine and antidepressant comparator drugs (group 1: MAO inhibitors and antidepressant combination, group 2: not established antidepressants and imipramine after TCP) in treatment resistant depression (Bro = brofaromine, Phe = phenelzine, Ven = venlafaxine, Mir = mirtazapine, 5HTP = 5-hydroxytryptophan, Nom = nomifensine, Imi = imipramine, Lam = lamotrigine; the numbers above confidence intervals indicate the numbers of responders and nonresponders after tranylcypromine (first pair) and comparator antidepressant drug (second pair)).
Figure 2 Effect sizes and summary effect size calculated as log odds ratios and pooled log odds ratio as well as their 95% confidence intervals for clinical studies of tranylcypromine and antidepressant comparator drugs in depression (Imi = imipramine, Ami = amitriptyline, Phe = phenelzine, Nor = nortriptyline, Moc = moclobemide, Bro = brofaromine; the numbers above confidence intervals indicate the numbers of responders and nonresponders after tranylcypromine (first pair) and comparator antidepressant drug (second pair)).
inhibitor response has been previously hypothesized by family correlations (Pare and Mack, 1971) . Three controlled studies have been conducted by one group of researchers for TCP exclusively in patients meeting the above criteria of atypical depression. The comparison of TCP (n = 28) with placebo (n = 31) resulted in 71.4% versus 12.9% responders, respectively (p o 0.001) (Himmelhoch et al., 1982) , and a comparison of TCP (n = 28) with imipramine (n = 28) resulted in 75.0% versus 35.7% responders, respectively (p o 0.01; logOR = 1.69 with 95%CI = 0.53 to 2.84) (Himmelhoch et al., 1991) . A small study of 12 patients with TCP and 4 patients with imipramine revealed 75% versus 25% responders, respectively (p = 0.07) (Thase et al., 1992a) . One limitation of these studies is the inclusion of only bipolar, atypical depression in two studies and the lack of confirmation by other research groups. In a non-controlled study of 40 patients, TCP in doses of 20-60 mg/day resulted in a superior rate of responders of a subgroup with intersection of atypical and anergic characteristics (n = 27) compared to a subgroup with typical characteristics (n = 13; rate of responders 67% and 31%, respectively; p o 0.05) (Thase et al., 1992b) . The previous review of TCP, which was limited to data from 1965, concluded that TCP may be useful in reactive and psychoneurotic depression, which are diagnostic entities similar to the recent definition of atypical depression (Atkinson and Ditman, 1965) . Double blind, randomized, and controlled trials have been conducted exclusively in patients with atypical depression for other MAO inhibitors and confirmed superior efficacy (e.g., phenelzine) (Krishnan, 2007; McGrath et al., 1987) . Taken together, these clinical, pathophysiological, and therapeutic data indicate a possible special quality of TCP in atypical depression.
Bipolar depression
Bipolar depression, as defined primarily by its time course with periods of mania or mixed episodes, may consist of anergic and atypical characteristics in a predominant portion of patients (Akiskal and Benazzi, 2005; APA, 2010; Grunze et al., 2010; Mitchell et al., 2008) . Some studies of TCP were even conducted in patients meeting both the bipolar and atypical characteristics and are therefore included already in the previous paragraph (Himmelhoch et al., 1991; Thase et al., 1992a ). An additional study enrolled bipolar patients but without concomitant atypical depression (Nolen et al., 2007) . Half of the patients in the placebo controlled study of 59 patients already discussed above for atypical depression suffered from bipolar depression with very good treatment effect of TCP [logOR = 2.83 with 95%CI = 1.49 to 4.16, TCP to placebo response-rate ratio (RR) = 5.5 with 95%CI = 2.1 to 14.2] (Himmelhoch et al., 1982) . Although this single study should not be overestimated, a recent systematic review of these 4 studies confirmed good efficacy and safety of TCP in bipolar depression (Heijnen et al., 2015) . A recent meta-analysis of placebo controlled studies in bipolar depression of all antidepressants calculated a mean antidepressant to placebo RR = 1.43 with 95%CI = 1.11 to 1.84, which included a phenelzine study with phenelzine to placebo RR = 2.29 with 95% CI = 0.97 to 5.4 (Vazquez et al., 2013) . A retrospective analysis of a large study of patients with bipolar disorder and bipolar depression was mentioned in paragraph 3.2 and found superior efficacy of TCP compared to paroxetine (Mallinger et al., 2009) . Current evidence suggests that TCP and other MAO inhibitors may only have a low risk of inducing switch into mania (Heijnen et al., 2015; Truman et al., 2007; Vazquez et al., 2013) .
Treatment-resistant depression
Therapeutic experience and non-controlled open studies suggest a therapeutic benefit from TCP in patients resistant to adequate TCA treatment (Adli et al., 2002; Thase et al., 1992b) . A recent study found 25% remission in 28 patients receiving 56 7 12 mg/day TCP for 8.9 7 2.6 weeks (mean 7 standard deviation) after a mean number of 7 treatments with SSRIs, SSNRIs, bupropion, TCAs, and others (Stewart et al., 2014) . A retrospective chart review of 32 university psychiatric clinic patients receiving an intensive TCP treatment [i.e., mean dose of 51.9 mg/day (20 to 100 mg/day), multiple comedications if needed, and a mean duration of treatment of 6.5 weeks (1 to 29 weeks)] reported 59.4% of patients in remission and 81% responders (Adli et al., 2008) . The meta-analysis of controlled studies presented in paragraph 3.1 and Figures 1 and 3 clearly confirmed the efficacy of TCP in TRD after failure on TCAs and SSRIs. The STAR*D-study with a responder ratio of only 12.1% (McGrath et al., 2006) takes an outlier position among other TCP-studies in TRD (mean responder ratio 58.1% (29.4-75.0)) (Birkenhäger et al., 2004; Himmelhoch et al., 1982; Nolen et al., 1985 Nolen et al., , 1988 Nolen et al., , 1993 Nolen et al., , 2007 Thase et al., 1992a; Volz et al. 1994a ). This may be explained by a nocebo effect for TCP in the STAR*D-study because it was stated explicitly that doctors and patients were uncomfortable with the MAO inhibitor in this open-label study. And the mean TCP dose in the STAR*D-study with 36.9 mg/day was the second lowest among TCP-studies in TRD. However, no antidepressant switch study has been conducted with a control of TCP by continuing the previous antidepressant. Since the introduction of the SSRIs in the 1980s, TCP has been mainly used in TRD because of the mandatory tyraminereduced diet and risk of hypertensive crisis, which limits TCP to a third line treatment. Some authors consider TCP as a first choice in stage-3 TRD according to the Thase and Rush classification (Birkenhäger et al., 2004) . A recent review questioned the practice of using MAO inhibitors after multiple failed trials only, by stating "The use of MAOI agents should not be a treatment of last resort after 10-12 failed antidepressant trials … " (Schwartz, 2013) .
Depression with special psychopathologic characteristics
Several case series on the successful treatment of special subtypes of depression with TCP have been published such as winter depression (Dilsaver, 1990) , delusional depression (Lieb and Collins, 1978) , recurrent brief depression (Joffe, 1996) , and melancholic depression . An inspection of these reports revealed, however, that many patients simultaneously shared diagnostic criteria of atypical and bipolar depression as well as TRD. Thus, this may have been more relevant for the success of TCP.
Tranylcypromine adjuvant to antipsychotic drugs in negative syndrome of schizophrenia
The use of TCP as a "psychic energizer" and an adjuvant to antipsychotic drugs, mainly trifluoperazine, has been reported in so-called defect schizophrenia as early as 1960 (Kruse, 1960; Singh and Free, 1960) . A pharmacoepidemiologic study in two German university clinics revealed in 1994 that 8% of TCP patients were suffering from schizophrenia (Schmidt et al., 1994) . This approach has been supported on a clinical and theoretical basis by the observation that atypical depression shares some characteristics with schizophrenia with negative symptoms (Parker et al., 2002) and by the hypothesis of dopaminergic and norepinephrinergic hypofrontality (Da Silva et al., 2008) . TCP is expected to improve negative schizophrenia by increasing prefrontal cortex dopamine and norepinephrine neurotransmission. A controlled study published in 1987 included 30 chronic schizophrenic outpatients with predominant emotional withdrawal, motor retardation, and blunted affect and only minimal positive symptoms. Patients were treated with 300 mg/day chlorpromazine, whereas half each received adjuvant 20 mg/day TCP or placebo over 4 months. Improvement was observed in 11 patients on TCP (73%) and no patients on placebo. After switching the placebo group to TCP for an additional 4 months, 13 patients (87%) showed improvement. Taking into account 10 previous studies, including 6 controlled (Buffaloe and Sandifer, 1961; Hedberg et al., 1971; Hordern et al., 1962; Mena et al., 1964; Schiele et al., 1963; Vogt, 1961) and 4 open (Barsa and Saunders, 1962; Bucci, 1969; Kruse, 1960; Singh and Free, 1960) studies, the authors concluded that labelling TCP only as an antidepressant is misleading (Bucci, 1987) . A recent non-interventional surveillance study of 53 patients investigated this approach for adjuvant TCP with second generation antipsychotic drugs. Improved impulse in 20 patients was found as a minor benefit of adjuvant TCP after ineffective trials with adjuvant SSRIs. The optimum treatment was defined for negative schizophrenic patients with no or minimal positive symptoms, TCP dose no more than 40 mg/day, antipsychotics at medium dose, no benzodiazepines, and a minimum duration of treatment of 2 to 3 months. The risk of exacerbation of positive symptoms was found to be very low and patients were considered to be compliant with the tyramine-restricted diet (Roesch-Ely et al., 2011) . Nevertheless, controlled trials are needed for a better definition of the benefit-risk ratio of TCP in negative schizophrenia.
Tranylcypromine in other psychiatric disorders
Parameters associated with increased MAO-A activity (e.g., increased MAO-A gene promoter alleles) have also been found in panic disorder and other neuropsychiatric disorders (Deckert et al., 1999; Naoi et al., 2016) . Therefore, if pharmacotherapy is instituted, some published cases and cases series suggest good experience with TCP as an alternative in selected patients of obsessive-compulsive disorder (Erfurth and Schmauss, 1993; Jenike, 1981) , anxiety with agoraphobia and panic disorder (Boerner and Luehring, 2010; Ries and Wittkowsky, 1986; Tyrer and Shawcross, 1988) , social phobia (Versiani et al., 1988) , borderline personality disorder (Cowdry and Gardner, 1988) , and narcolepsy (Clemons et al., 2004; Gernaat et al., 1995) . No controlled studies have been conducted, with the exception of one study in social anxiety disorder, which resulted in 70% of patients receiving 30 mg/day or 60 mg/day TCP over 12 weeks being free of panic attacks (Nardi et al., 2010) . Better data in terms of controlled trials are available for phenelzine (Blanco et al., 2013) and TCP in addition to phenelzine is therefore included in national and international treatment guidelines of anxiety disorders (Bandelow et al., 2008) . TCP is used for these conditions as a reserve treatment only by experienced psychiatrists, however, also known "in these cases as very useful". It is suggested that the therapeutic effect is derived not only from MAO inhibition with subsequent enhanced serotonergic and norepinephrinergic tone in the CNS, but also from additional mechanisms such as norepinephrine reuptake inhibition. Whether comorbid depression may be a predictor of good or poor response has not been clarified.
Tranylcypromine in neurology
Neuroprotection by MAO inhibitors is a growing area in neuropharmacology research because reduced metabolic burden by neurotransmitter metabolites and reactive oxygen species is inherent to inhibition of amine metabolism (Baker et al., 2007) . In addition, TCP, similar to other MAO-A/B and MAO-B inhibitors, was shown to protect against 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity (Heikkila et al., 1984) and is known to increase dopamine levels. TCP was therefore expected to be effective in studies of Parkinson's disease. One study found that 30 mg/day TCP used instead of the selective MAO-B inhibitor selegiline slightly improved early signs and symptoms in 37 patients with Parkinson's disease who did not require levodopa treatment, and only minimal progression was observed over 33 months. In addition, an indirect comparison with historic data in similar patients for selegiline or tocopherol (vitamin E) treatment found a higher number of patients requiring levodopa with selegiline. Comorbid depression could be treated successfully with TCP (Fahn and Chouinard, 1998) . At low doses, the (+)-TCP isomer was more active in alleviating motor symptoms than the (-)-TCP isomer, which was explained by more potent MAO inhibition (Reynolds et al., 1981) . Comedication of fixed combinations of levodopa with decarboxylase inhibitors is possible with TCP. However, because the selective MAO inhibitors selegiline and rasagiline can be administered without tyramine restrictions, TCP is not recommended for the treatment of Parkinson's disease. Finally, although depression has been successfully treated with TCP in two patients with Alzheimer's dementia, a preliminary study in 7 non-depressed patients with Alzheimer's dementia had a disappointing outcome (Jenike, 1985; Tariot et al., 1988) .
Practice of tranylcypromine treatment 4.1. Therapeutic doses
According to the amine hypothesis, increased serotonin and norepinephrine levels induce changes in neuroplasticity related to improvement in depression as explained in paragraph 3.3 of part I. Increased dopamine may add to this target because dopaminergic hypofrontality was found in negative schizophrenia, which shares some characteristics with depression (Da Silva et al., 2008) , and decreased dopamine is discussed in bipolar depression (Berk et al., 2007) . Enhanced phenylethylamine, which is known as an "endogenous amphetamine", and reduced oxidative stress may also explain some aspects of the antidepressant activity of TCP (Bortolato et al., 2008) . This basic activity as a MAO inhibitor is achieved with doses of 10-20 mg/day TCP in most patients. Moreover, the data of TCP neurobiochemistry (paragraph 3.1 of part I) and pharmacokinetics together with the finding that TCP levels in brain were 3-fold higher than in plasma (paragraph 3.4 of part I) indicate that norepinephrine reuptake inhibition contributes to TCP pharmacology at plasma levels of more than 40 ng/ml, which can be achieved at doses of 40-60 mg/day. As a third aminergic mechanism, the amphetamine-like dopamine releasing activity of TCP is very unlikely to occur at these doses. However, it may be relevant for some patients who already have high plasma concentrations at low dose and who are treated with 100 mg/day TCP as in some controlled clinical trials (Birkenhäger et al., 2004; Freyhan et al., 1960; Nolen et al. 1985 Nolen et al. , 1993 or over 100 mg/day according to a concept of high-dose treatment (Amsterdam and Berwisch, 1989; Gutze and Baxter, 1987; Pearlman, 1987; Robinson, 1983; Schmauss, 1996) . It is estimated that at least 400 ng/ml TCP in plasma is needed for dopamine releasing activity in the CNS. In a recent dose escalation study of TRD, 7 of 28 patients (25%) remitted with o 60 mg/day TCP and 6 of the remaining 19 patients (32%) in a high-dose treatment with 105 7 20 mg/day TCP (mean 7 standard deviation). Two patients refused high-dose treatment (Stewart et al., 2014) . Unfortunately, no controlled dose finding studies have been conducted for TCP to date and no data are available for high doses on the long term. Of the controlled studies already discussed, approximately one third each used low doses of o 30 mg/day, medium doses of 30-60 mg/day, and higher doses of up to 100 mg/day (Table 2) ; however, an analysis with respect to dose is complicated by the heterogeneity of studies. A previous review concluded that optimal response appears in patients who can tolerate 40-60 mg TCP, which is also the maximum dose according to recent prescribing information of marketed TCP drug preparations for patients who can be closely supervised (Thase et al., 1995) . It is therefore advised to titrate TCP dose with respect to therapeutic effect and tolerability to a maximum dose of 60 mg/day in inpatients.
Adverse effects
A typical profile of adverse effects of 30 to 60 mg/day TCP (n = 63) compared with nortriptyline (n = 61) and placebo (n = 59) over four weeks of treatment in a randomized controlled trial is shown in Figure 4 . Dizziness, sleeping disorders, and dry mouth were noted at least once in over 50% of patients through a weekly questionnaire, including reactions of minimal or low severity and without regard to causality (White et al., 1984) . Dizziness was related to orthostatic hypotension in the majority of patients and, as described in similar studies, is the main reason of intolerance to TCP and study drop-out. Higher percentages of insomnia and overexcitement sharply differentiated TCP from the TCA. Overexcitement included objective signs of motor hyperactivity and subjective mental complaints. On the other hand, patients with nortriptyline suffered more often from anticholinergic effects such as dry mouth, constipation, and blurred vision. However, dry mouth was still high in patients receiving TCP treatment despite the fact that TCP displays no anticholinergic activity. This is explained by a specific norepinephrinergic increase in sympathetic activity of salivary glands due to TCP, which decompensates the sympathetic-parasympathetic balance and may therefore mimic a peripheral anticholinergic reaction. Since this mechanism is excluded for central anticholinergic effects, confusion was found at placebo level only for TCP. In a study design focusing solely on medically significant adverse effects, a somewhat different profile and lower frequency of adverse effects were found for a similar dose of TCP: 17% orthostatic hypotension (passing out, falling), 7% hypomania, 5% paresthesias, and 2% hypertensive reactions, confusion, urinary retention, sexual function disorders, and rash. No correlation was observed between adverse effects, patients below the age of 65, and sex (Rabkin et al., 1984) . Other controlled studies confirmed this profile of the most frequent adverse effects and identified additional less frequent effects in TCP patients, such as edema, anorexia/loss of appetite, increased appetite, leg cramps/muscle pain, hyperreflexia, diarrhea, sensation of cold, tinnitus, and chest pain (Bartholomew, 1962; Birkenhäger et al., 2004; Gottfries, 1963; Heinze et al. , Figure 4 Adverse effects of tranylcypromine (n = 63 patients) in a placebo (n = 59) and nortriptyline (n = 61) controlled, randomized, double-blind, short-term trial with intensive study of adverse effects and including mild-to-moderate severity (significant differences of TCP vs. nortriptyline for dizziness (p o 0.05), insomnia (p o 0.01) and overexcitement (p o 0.05) and TCP vs. placebo for dizziness, insomnia and dry mouth (p o 0.01); 4.5 adverse effects per patient for TCP, 4.8 nortriptyline and 2.3 placebo (nonsignificant)) (White et al., 1984 (White et al., ). 1993 O'Brien et al., 1993; Nolen et al., 1985 Nolen et al., , 1988 Razani et al., 1983; Volz et al., 1994a) . No weight gain was found in randomized controlled trials of TCP Volz et al., 1994a) and was of little relevance for TCP in post-marketing surveillance studies in contrast to, for example, phenelzine (Cantu and Korek, 1988; Rabkin et al., 1984) . A recent review found phenelzine, but not TCP, among antidepressants associated with a greater risk of hepatotoxicity (Voican et al., 2014) . In addition, there are no reports of increased bleeding with TCP to date. The mean increase in QTc interval was only 4.2 ms (p40.05) with TCP in psychiatric patients, which is below an accepted threshold of a clinically relevant QTc increase of 5 ms. In contrast, 12.5 ms (p = 0.01) were found for amitriptyline as positive control . The ECG also did not change in a controlled study of 46 TCP patients (Volz et al., 1994a) . Surprisingly, high blood pressure was not important in the majority of studies. This is explained by three forms of hypertension that are all unlikely to occur or to be detected during regular TCP treatment: (i) an early-onset hypertensive activity of TCP, (ii) a late-onset hypertensive activity of TCP, and (iii) the well-known hypertensive reaction resulting from tyramine by violations of the tyramine-restricted diet. Since the early-onset hypertensive activity of TCP is mild and lasts for only one to two hours after ingestion, it is often overlooked in most cases or noticed as palpations. The late-onset spontaneous form is very rare and the tyramine reaction can be avoided by dietary restrictions (Keck et al., 1991; Taylor et al., 2005) .
Sufficient data are currently lacking on the direct comparison of adverse effects of TCP with SSRIs, SSNRIs, and other antidepressant drugs introduced after 1990. Although TCP is not an alternative to these drugs as a first-line treatment, this comparison is important in a theoretical perspective as well as in practice when it is imperative to make decisions at the right time of a TCP trial after multiple SSRIs or SSNRIs are used. A long-term open study in outpatients that assessed TCAs (n = 128), SSRIs (n = 30), MAO inhibitors (TCP: n = 22, phenelzine: n = 8, moclobemide: n = 6), and atypical antidepressants (bupropion: n = 10, trazodone: n = 3, nefazodone: n = 1) may therefore be used as an estimate. Adverse effects were observed in 85% of visits for TCAs, 71% for SSRIs, 67% for MAO inhibitors, and 66% for atypical antidepressants. Most prominent differences of TCP and SSRIs in a profile of frequent adverse effects ( Figure 5 ) are a higher incidence of dry mouth and a lower incidence of sedation, headache, anxiety, nausea, and sweating for TCP (Mittmann et al., 1999) . The absence of overexcitement and insomnia for TCP compared to the study described above (White et al., 1984) can be explained by the two year treatment duration. These adverse effects may therefore vanish after long-term treatment or could lead to discontinuation of TCP. A controlled study according to the STAR*D protocol compared TCP with a combination of venlafaxine and mirtazapine. There were no significant differences in frequency, intensity, or burden of adverse effects or in the frequency of serious adverse events. The discontinuation rate for patients receiving TCP due to side effects was double the discontinuation rate of patients receiving the combination, however, in an environment that stated explicitly to be "uncomfortable" with the MAO inhibitor which may be translated to a nocebo effect for TCP (McGrath et al., 2006 ). An indirect comparison of adverse effects observed in clinical studies of antidepressant drugs resulted in codification of the strength of the adverse effects (Bauer et al., 2013) (Table 4) . Although the selection of adverse effects was not comprehensive (e.g., lacking central anticholinergic, cardiac conduction, and hemostasis effects) and the evaluation of strength was only an approximation, the sum score of the most relevant adverse effects may be calculated as a measure of the mean adverse effect burden. Taken together, data suggest that TCP has some advantages over TCAs and exhibits no disadvantages compared to SSRIs and SSNRIs as the most established antidepressants. In practice, the evaluation of the individual risk and treatment situation of a patient taken into account for a possible trial of TCP may also strongly consider the adverse effect profile in Table 4 .
Management of frequent adverse effects
The pathophysiological mechanism of orthostatic dysregulation during TCP treatment is not known. Accumulation of false neurotransmitters such as octopamine in peripheral nerve terminals (Cockhill and Remick, 1987) , a direct interaction of TCP with postsynaptic alpha-adrenergic receptors (Keck et al., 1991) , and central and/or peripheral norepinephrine reuptake inhibition (Krishnan, 2007; Schlessinger et al., 2011) have been discussed. To cope with this frequent adverse effect, correction of contributing factors found in the patient's anamnesis, education of patients, increased fluids, exercise, temporary use of elastic support stockings, NaCl supplementation, caffeine, dihydroergotamine, direct sympathomimetics (i.e., midodrine and etilefrin), and fludrocortisone have been recommended (Cockhill and Remick, 1987; Cole and Bodkin, 2002 ; Figure 5 Adverse effects of TCAs (n = 128 patients), SSRIs (n = 30), MAO inhibitors (n = 36, 61% tranylcypromine) and atypical antidepressants (n = 14, 71% bupropion) in an open, non-interventional, long-term trial with intensive study of adverse effects and including mild to moderate severity (mean number of adverse effects per visit = 2.6), comparison tranylcypromine vs. SSRIs: sedation and headache (p o 0.01 each), dry mouth, anxiety, nausea and sweating (p o 0.001 each), 61.5%, 16.4%, 37.4% and 17.5% of patients with treatment of TCAs, SSRIs, tranylcypromine and bupropion, respectively, received lithium augmentation (Mittmann et al., 1999) . Feinberg, 2004; Rabkin et al., 1985) . It should be noted, however, that long-term dihydroergotamine (organ fibrosis), direct sympathomimetics (hypertensive reaction), and longterm fludrocortisone (steroid-related adverse effects) escalate adverse effect management with their own risks. Some authors have even described the safety and efficacy of a very controlled application of the indirect sympathomimetics d-amphetamine and methylphenidate, which are strictly contraindicated with TCP (Ayd, 1973; Cole and Bodkin, 2002; Feinberg, 2004) . Failure and adverse effects of these treatments have to be considered and dose adjustment of TCP may be needed instead of that. Dividing doses may also be considered since it was found that increased peak plasma concentrations correlated with orthostatic hypotension (Mallinger et al., 1986) .
Sleep disorders together with possible secondary drowsiness the following afternoon have been treated with benzodiazepines in controlled trials (e.g., Birkenhäger et al., 2004; O'Brien et al., 1993) and low-dose trazodone in two open studies (Jacobsen, 1990; Nierenberg and Keck, 1989) . Very little data are currently available for benzodiazepine-like drugs, such as zopiclone, together with TCP (Adli et al., 2008) ; however, no interactions have been spontaneously reported. Based on experience with chlorpromazine (Bucci, 1987) and olanzapine (Roesch-Ely et al., 2011) , low doses of sedative low potency or second generation antipsychotics may be another option for insomnia due to TCP in depressed patients. These drugs may also relieve patients from TCP-related overexcitement. Taking the last dose of TCP not later than 3 or 4 p.m. can be tried to reduce the risk of insomnia, but this remains a controversial issue (Cole and Bodkin, 2002; Jenike, 1984; Nolen et al., 1988) . Direct parasympathomimetics, such as bethanechol, have been recommended in the literature for dry mouth (Cole and Bodkin, 2002) . Pilocarpine drug products are also available for this indication, but an interaction with TCP through CYP2A6-dependent metabolism is possible. The own early-onset hypertensive activity of TCP, which may occur frequently, rarely reaches symptomatic levels and has been successfully treated by dividing doses or with calcium channel blockers or betablockers (Stewart et al., 2014; Taylor et al., 2005) .
Risk of drug-drug interactions
The risk of pharmacokinetic drug interactions in the direction from TCP to other drugs is low as found in paragraph 3.2 of part I of the review. Insufficient data is available to evaluate the risk of pharmacokinetic drug interactions in the direction from other drugs to TCP (paragraph 3.4 of part I).
Concerning pharmacodynamic drug interactions, as also reviewed in part I (paragraph 3.5), safe treatment with TCP first of all requires the prevention of two principle mechanisms of drug interaction: (i) serotonergic activation by Table 4 Comparison of TCP with other antidepressant drugs according to a codification of adverse effect strength with the categories + + + (high/strong), + + (moderate), + (low/mild), and -(very low/none), WFSBP-guideline for biological treatment of unipolar depressive disorders (Bauer et al., 2013 
irMAO-A/B inhibitor irreversible monoamine oxidase A/B inhibitor, rMAO-A inhibitor reversible monoamine oxidase A inhibitor, TCA tricyclic antidepressant, SSRI selective serotonin reuptake inhibitor, SSNRI selective serotonin norepinephrine reuptake inhibitor, SNDRI selective norepinephrine dopamine reuptake inhibitor, NSSA norepinephrinergic and specific serotoninergic antidepressant. a symptoms commonly caused by muscarinic receptor blockade including dry mouth, sweating, blurred vision, constipation and urinary retention. serotonin reuptake inhibitors (e.g. SSRIs, SSNRIs) or serotonin precursors, and (ii) norepinephrinergic activation by indirect sympathomimetics (e.g. ephedrine, phenylpropanolamine). Norepinephrine reuptake inhibition does not represent a substantial risk (Gillman, 2007; Schmauss et al., 1988) . Serotonergic activation by serotonin release is of low practical relevance because most indirect sympathomimetic drugs preferentially release norepinephrine, and only amphetamine may additionally release serotonin (Gillman, 2006) .
Risk of food interaction of tranylcypromine with tyramine
A very special property of TCP is the risk of food interaction with tyramine and other biogenic amines found in some foods, such as aged cheese, aged or cured meat and fish, highly concentrated yeast extract products, soy sauce, sauerkraut, and alcoholic beverages. The pharmacology of this interaction has already been summarized in paragraph 3.6 of part I of the review. Therefore, the fundamental requirement of TCP treatment is a mandatory tyraminerestricted diet. Lists of foods to be avoided have been improved recently by a critical reappraisal of old clinical and chemical-analytical data as well as reference to modern methods of manufacture and storage of food. In doing so, modern food, including normal servings of bottled/canned beer, wine, distilled spirits, and chocolate are now regarded as less likely to have high tyramine content by some authors. It has also been discussed that the effort needed to maintain a tyramine-restricted diet may have been exaggerated in the perception of some doctors and patients, thus leading to underuse of TCP (Flockhart, 2012; Gardner et al., 1996; McCabe-Sellers et al., 2006) . In organizational routine, 88% of patients and 94% of caregivers evaluated tyramine-restricted diet as simple or well-manageable (Adli et al., 2008) .
The incidence of hypertensive reactions after consumption of tyramine-rich food in patients receiving an MAO inhibitor was approximately 8% prior to the introduction of dietary restrictions (Blackwell et al., 1967) and decreased to approximately 1-2% in the 1980s (Robinson and Kurtz, 1987) . For example, despite information on the necessary diet, one of 41 patients on a TCP study deliberately violated the restrictions by eating cheese and suffered from a moderately severe reaction without sequelae (Rabkin et al., 1985) . It is interesting that an incidence of 6.6% of hypertensive reactions in outpatients treated with TCP and phenelzine (12 of 182 during two years, including one severe reaction) decreased to zero during the following two years after incorporation of more vigorous and explicit warnings (Harrison et al., 1989) . Concerning the most severe cases (i.e., organ damage and death), a review of data from the 1970s estimated the risk of death to be 0.007% after inclusion of suspicious cases without confirmation of a causal relationship to TCP (Pare, 1985) . Another retrospective study published in the 1970s found 50 cases of severe cerebrovascular complications (0.0014%), including 15 deaths (0.0004%), in 3.5 million patients treated with TCP, also without confirmation of a causal relationship (Baldessarini, 1996) . In addition, a German study reported 6 cases of intracranial hemorrhage in 102,000 TCP patients (0.006%) (Haase and Buhr, 1973) . No cases of a severe tyramine reaction were found in a more recent analysis of TCP treatment in a retrospective chart review of 348 patients older than 65 years (Shulman et al., 2009) . It is of interest in this respect that SSRIs were also found to bear a very low risk of intracranial hemorrhage because of inhibition of the platelet serotonin reuptake transporter (Hackam and Mrkobrada, 2012) . The risk of tyramine interaction determines for the main part the benefit-risk-ratio and place in therapy of TCP as discussed in more detail in paragraph 5.
Risk of drug dependence and abuse
A recent review identified 18 published cases of withdrawal syndrome, including 10 patients with delirium, after TCP dependence/abuse at doses of 120 to 600 mg/day. Previous or current substance dependence/abuse from psychotropic drugs other than TCP was identified in 14 of these patients (78%). Discontinuation phenomena without dependence/ abuse were found in 7 reports, including three patients with delirium, at doses of 20 to 140 mg/day (Gahr et al., 2013) . The amphetamine-like activity of TCP together with favorable pharmacokinetics (fast absorption, short half-life) is regarded as the mechanistic basis of TCP dependence/ abuse. As for amphetamine anorectic medications (O'Brian, 1995) , however, the risk seems to be limited to rare cases. In conclusion, TCP should not be prescribed to patients with a history of substance dependence/abuse and cluster B personality traits (borderline, narcistic, histrionic), and a slow incremental dose reduction is advised for discontinuation of TCP. High-dose treatment with TCP as reported in very rare cases (see paragraph 4.1) may be a critical approach with respect to the risk of dependence and abuse.
Tranylcypromine in elderly patients
MAO-B activity is well-known to be increased with age (Mahy et al., 2000; Robinson et al., 1972; White et al., 1980b) , which may provide a pathophysiological rationale for the use of TCP in the treatment of depression of older patients (Jenike, 1984 (Jenike, , 1985 as well as neurodegenerative disorders (Baker et al., 2007; Fahn and Chouinard, 1998) . Moreover, the risk of some adverse effects and drug interactions relevant for elderly patients and known for other antidepressants are minimal or absent for TCP, such as central anticholinergic effects, direct peripheral anticholinergic reactions, ECG changes, increased bleeding, and pharmacokinetic interactions. There is therefore no principal restriction for TCP treatment with regard to age of patients in the absence of contraindications that may be more often encountered in the elderly, such as severe cardiovascular disorders, high blood pressure, hepatic and severe renal insufficiency, or cerebrovascular disorders. In addition, cognitive impairment more often encountered in older patients may detract from the mandatory tyramine-restricted diet. Sustained trouble with severe orthostatic hypotension should be added as a reason for the withdrawal of TCP and general caution is advised because older patients have less compensatory reserve to cope with any serious adverse reaction.
Very few patients over the age of 65 have been included in controlled studies of TCP. However, successful treatment of old patients with TCP has been described in several case report series (Ashford and Ford, 1979; Harms et al., 2000; Jenike, 1984 Jenike, , 1985 Lieb and Collins, 1978; Oostervink et al., 2003) . A non-interventional clinical study exclusively in patients over the age of 65 years included 22 patients treated with TCP for two years (Mittmann et al., 1999) . Moreover, a recent observational cohort study in 348 patients over the age of 65 years found the use of TCP to be safe (Shulman et al., 2009) . Another non-interventional study included 27 patients over the age of 70 years and also found no increase in the frequency of adverse effects in patients greater than 65 years compared to patients between the ages of 40 to 60 years who had all been screened for active coronary or cerebrovascular insufficiency. The author of this study concluded in 1978 that "the admonition that TCP should not be used in patients over 65 should be withdrawn" (Lesse, 1978) and other authors concluded in 2009 that TCP and phenelzine should be used more for atypical and treatment-resistant depression of older patients (Shulman et al., 2009 ).
Tranylcypromine and anesthesia/analgesia
New studies have provided evidence that the use of general and local anesthesia in a controlled manner and with careful evaluation of the individual risk may be safe in psychiatric patients without discontinuation of TCP. The high psychiatric risk of discontinuation of TCP in TRD is likely to outweigh the increased yet manageable perioperative risk from continuing TCP during anesthesia/analgesia (El-Ganzouri et al., 1985; Krings-Ernst et al., 2013; Pass and Simpson, 2004; Stack et al., 1988; Van Haelst et al., 2012) . Controlling factors include the exclusion of several drugs used in anesthesia/ analgesia (e.g., indirect sympathomimetics for hypotension substituted by direct sympathomimetics, serotonergic opioids substituted by non-serotonergic opioids), exclusion of cardiac surgery or other conditions that constitute an independent contraindication of TCP, and maintenance of sympathetic homeostasis through the use of sufficient preoperative antianxiety medications and perioperative avoidance of pain, hypoxia, hypercapnia, and hypotension. Maintenance of sympathetic homeostasis may also require avoidance of short-term discontinuation of TCP prior to anesthesia/ analgesia because complete sympathetic readjustment actually requires more than two weeks. A previous report showed that discontinuation of TCP even three weeks before surgery still retained some perioperative risk in a multi-morbid 79 year-old patient (Sprung et al., 1996) . Therefore, a general endorsement of MAO inhibitor discontinuation before anesthesia/analgesia has been regarded as challenging or even inadequate (Krings-Ernst et al., 2013; Pass and Simpson, 2004; Stack et al., 1988; Van Haelst et al., 2012) . Other authors still prefer MAO inhibitor discontinuation of two weeks (Huyse et al., 2006) , which was adopted in recent anesthesiology guidelines; however, there is minimal evidence to support this recommendation to date (De Hert et al., 2011) . Taking into account the special properties of a drug (e.g., TCP being less prone to pharmacokinetic interactions than phenelzine) may also help in the difficult decision on discontinuation or continuation of TCP during the use of anesthesia/analgesia.
Tranylcypromine and electroconvulsive therapy (ECT)
The administration of ECT and 20 mg/day TCP when started together was found to be safe and had similar efficacy as ECT with placebo in a controlled trial over four weeks (Monaco and Delaplaine, 1964) . Thousands of patients thereafter received this combination as mentioned in a report of 1975 (Sargant, 1975) . TCP in combination with ECT was also safe in 13 patients compared to a control group of 45 patients receiving ECT alone in a report from 1985 (El-Ganzouri et al., 1985) . According to more recent data of 5 patients, multiple ECT sessions were safe during treatment with higher doses of up to 80 mg/day TCP and depression resolved after insufficient improvement or worsening with TCP alone (Dolenc et al., 2004; Ribeiro et al., 2008) . Therefore, it can be concluded that ECT augmentation may be a suitable approach for patients who do not respond to TCP alone.
The benefit-risk ratio of tranylcypromine and place in therapy
Since it is well-accepted that the efficacy of antidepressants is approximately equal in controlled trials, only the risks need to be discussed for a comparison of benefit-risk ratio. The risk of TCP is mainly due to a potential for a tyramine hypertensive reaction, and therefore TCP has considerably higher risk than TCAs, SSNRIs, or SSRIs. On the other hand, the risk of a chronic course of depression is increased with a higher number of failed antidepressant trials (Bauer et al., 2013; Mathys and Mitchell, 2011) , and suicidality reached 50-62% in patients with treatment-resistant depression (TRD) (Price et al., 2009) . Thus, the risk of the disease is considerably higher in TRD and it may compensate for the increased risk of the drug at a certain stage of TRD. Therefore, it is advised not to delay or even omit an established treatment that includes a completely new pharmacological approach, such as MAO inhibition. The advantages of TCP should also be considered, such as low risk of pharmacokinetic interactions, low risk of weight gain, and no central anticholinergic effects. In comparison to lithium augmentation, TCP treatment avoids polypharmacy, long-term nephrotoxicity, and plasma level assays.
In a synthesis of this evaluation, irreversible MAO inhibitors have been incorporated as the 4th treatment step in algorithms of antidepressant treatment after administration of two other antidepressants and lithium augmentation (Adli et al., 2002; Bauer et al., 2009; Kennedy et al., 2001; Spijker and Nolen, 2010; Trivedi et al., 2006) . One algorithm even recommends earlier trials with MAO inhibitors in case of atypical depression (Spijker and Nolen, 2010) . Superiority of treatment according to such algorithms was found compared with treatment as usual (Bauer et al., 2009; Trivedi et al., 2006) and systematic treatments are also recommended in recent guidelines and state of the art articles (Bauer et al., 2013; Kupfer, 2005) . Moreover, international guidelines, such as in the American Psychiatric Association (APA) and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines, include irreversible MAO inhibitors as a third-line antidepressant (Thase, 2012) .
Conclusions and future development of tranylcypromine
Recent scientific evaluation continues to support the use of TCP in TRD with atypical depression as a domain of TCP use. Bipolar and anergic depression may also be added because they are likely to be related to atypical depression in many patients and since TCP showed positive results in these conditions. Although no differential pharmacotherapy of depression is available based on biological correlates, recent studies of an association of increased MAO activity with traits and severity of depression, together with clinical experience, point to the existence of a subset of patients who may particularly benefit from MAO inhibitor treatment. Clinical and pathophysiological scenarios have been hypothesized that utilize the MAO inhibitor in an individualized treatment plan. The identification of these "MAO inhibitor patients" who would likely benefit from MAO inhibition is a clinically intuitive approach today. Psychiatrists should therefore become familiar with TCP treatment approaches and evaluate the benefit-risk-ratio in each case (Schwartz, 2013) .
Clinical practice has surpassed the scientific development of TCP in many areas. For example, no controlled studies have been conducted to date to compare the efficacy of SSRIs/SSNRIs with TCP because they are not first-line treatment competitors due to safety reasons. However, this represents a theoretical gap. A switch study to TCP while continuing the comparator antidepressant, studies of PET imaging of MAO activity in TCP patients, and clinical studies addressing neuroprotection with TCP are all studies that should be considered in the future. Moreover, taking into account the therapeutic potential of TCP, sufficient MAO inhibition in the CNS without MAO inhibition in liver and gut, to overcome tyramine restricted diet, still appears to be a basic research target. The authors of this review are currently conducting a comparative study of TCP and lithium augmentation in TRD patients (TraveL study, tranylcypromine versus lithium augmentation). Finally, very interesting research with TCP has been growing outside the area of neuropsychopharmacology during the past decade, and these studies of TCP and TCP derivatives as LSD1 inhibitors may open new therapeutic approaches.
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